Publication
Lenvatinib plus pembrolizumab for the treatment of patients with non-BRAF mutated anaplastic thyroid cancer: A single center, phase 2 clinical trial.
Maria E Cabanillas, Naifa L Busaidy, Mark Zafereo, Priyanka C Iyer, Jennifer R Wang, Sarah Hamidi, Renata Ferrarotto, Suyu Liu, Gary B Gunn, Michael Spiotto, Anna Lee, Anastasios Maniakas, Maria Gule-Monroe, Michelle D Williams, S Mohsen Hosseini, Victoria E Banuchi, Mimi I Hu, Matthew Ning, Ramona Dadu
- Source
- PubMed
- Retrieved
- Sep 19, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260919-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
BACKGROUND: Dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) is approved for BRAF V600E-mutated anaplastic thyroid cancer (ATC), but ∼60% of tumors do not harbor BRAF V600E, leaving these patients without effective treatment options. METHODS: This was a phase 2 study of patients with…
Read on PubMedLinked entities
Linked entities (2)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- trialNCT04171622registry_reference1.00
Candidate 1
- cancerMalignant Thyroid Gland Neoplasmdictionary0.60
Registered trialsNCT04171622
Curated evidence
Evidence citing this paper (0)
Data not yet available